← Back to Search

mTOR Inhibitor

PTX-022 for Pachyonychia Congenita

Phase 3
Recruiting
Research Sponsored by Palvella Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up prior to dose, 12 hours and 24 hours
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing a special skin gel called QTORIN rapamycin on adults with a rare genetic skin disorder to see if it is safe and how it works.

Eligible Conditions
  • Pachyonychia Congenita

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~prior to dose, 12 hours and 24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and prior to dose, 12 hours and 24 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Pharmacokinetic parameters

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: PTX-022Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PTX-022
2019
Completed Phase 3
~200

Find a Location

Who is running the clinical trial?

Palvella Therapeutics, Inc.Lead Sponsor
7 Previous Clinical Trials
341 Total Patients Enrolled
3 Trials studying Pachyonychia Congenita
196 Patients Enrolled for Pachyonychia Congenita

Media Library

PTX-022 (mTOR Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05643872 — Phase 3
Pachyonychia Congenita Research Study Groups: PTX-022
Pachyonychia Congenita Clinical Trial 2023: PTX-022 Highlights & Side Effects. Trial Name: NCT05643872 — Phase 3
PTX-022 (mTOR Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05643872 — Phase 3
~15 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top